Clinical trials: Recurrent Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma.
- Trial name
- NCT03463265
- Testing
- nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aadi Bioscience, Inc.
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Glioma
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
- Trial name
- NCT00526812
- Testing
- RTA 744, RTA 744 injection
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Biogen
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Malignant Glioma, Anaplastic Astrocytoma
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
The purpose of the study is to confirm the safety of the selected dose and potential toxicity of oncolytic poliovirus (PV) immunotherapy with PVSRIPO for pediatric patients with recurrent WHO grade III or IV malignant glioma, but…
- Conditions
- Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT03043391
- Testing
- Polio/Rhinovirus Recombinant (PVSRIPO)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Istari Oncology, Inc.
High Grade Glioma, Glioblastoma Multiforme
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
This is a study of DSP-0390 in patients with recurrent high grade glioma.
- Trial name
- NCT05023551
- Testing
- DSP-0390
- Where
- 9 sites in United States, Japan
- Volunteers
- 39 people
- Sponsor
- Sumitomo Pharma America, Inc.
Glioblastoma, Glioblastoma Multiforme
Treatment of Recurrent GBM With APG-157 Via Expanded Access
This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.
- Trial name
- NCT05551013
- Testing
- APG-157
- Sponsor
- Aveta Biomics, Inc.
Glioblastoma, Small Cell Glioblastoma
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ReACT (NCT01498328)
- Testing
- Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
- Where
- 45 sites in United States
- Volunteers
- 127 people
- Sponsor
- Celldex Therapeutics
Malignant Glioma
G207 Followed by Radiation Therapy in Malignant Glioma
This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.
- Trial name
- NCT00157703
- Testing
- G207
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- MediGene
Glioblastoma, Astrocytoma
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.
- Trial name
- NCT00335075
- Testing
- Temozolomide, Semustine
- Volunteers
- 151 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
Glioblastoma, Glioblastoma Multiforme
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
- Trial name
- 105GM201 (NCT01564914)
- Testing
- TRC105, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Recurrent Glioblastoma Multiforme
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
This is a multi-center, phase Ib/ II study (two parts) with patients that had recurrent glioblastoma multiforme. The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once…
- Trial name
- NCT01934361
- Testing
- buparlisib, carboplatin, lomustine
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme, Astrocytoma
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations.
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Gliomas, Malignant
- Trial name
- NCT04327011
- Testing
- Toca 511 vector, Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Tocagen Inc.
Glioma
Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.
The purpose of this trial is to determine the safety and feasibility of injecting irinotecan hydrochloride drug-eluting beads directly into the cavity remaining after a tumor is surgically removed in patients with a type of brain…
- Trial name
- NCT02433392
- Testing
- CM-BC2
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Boston Scientific Corporation
Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
- Trial name
- NCT05109728
- Testing
- [177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
Glioblastoma Multiforme, Glioblastoma
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT04446416
- Testing
- NaviFUS System, Bevacizumab
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Glioblastoma, Glioma
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
- Trial name
- KING (NCT01986348)
- Testing
- Selinexor
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 76 people
- Sponsor
- Karyopharm Therapeutics Inc